StockData
LB Pharmaceuticals Inc logo

LB Pharmaceuticals Inc (LBRX) stock

LBRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$40.30−2.69 (-6.26%)

Close on Nov 17, 2026Market cap $1.30BP/E –Yield –

LB Pharmaceuticals r&d expenses

Research and development expenses are spending on new products and technology.

LB Pharmaceuticals's R&D Expenses for the twelve months ending Jun 30, 2026 was $69.69M, up 312.8% year over year. For fiscal 2025 it was $16.74M, down 67.3% from the year before.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$16.74M-67.3%
FY2024Dec 31, 2024$51.17M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$44.15M+1723.5%
Q1 FY2026Mar 31, 2026$14.65M+328.1%
Q4 FY2025Dec 31, 2025$8.48M+2156.1%
Q3 FY2025Sep 30, 2025$2.42M-77.3%
Q2 FY2025Jun 30, 2025$2.42M–
Q1 FY2025Mar 31, 2025$3.42M–
Q4 FY2024Dec 31, 2024$376.00K–
Q3 FY2024Sep 30, 2024$10.66M–

More LB Pharmaceuticals figures

See a number that looks wrong?